title: Effect of hepatocyte growth factor on invasion of prostate cancer cell lines.
abstract: Hepatocyte growth factor (HGF) was suggested to play an important role in the regulation of mitogenesis, motogenesis, angiogenesis, migration and invasion for various types of cells, and acts through a specific membrane receptor encoded by c-met proto-oncogene. However, the mechanism of the effect of HGF on tumor invasion of prostate cancer cells remains unclear. We investigated the effect of HGF on the invasion of PC-3 and DU-145 prostate cancer cells through a reconstituted basement membrane (Matrigel), the haptotactic migration to fibronectin substrate, the expression of protein and mRNA for matrix metalloproteinases (MMP)-1 and -9, membrane-type 1-MMP (MT1-MMP), urokinase-type plasminogen activator (u-PA) and its receptor (uPAR). HGF increased both Matrigel invasion and haptotactic migration of prostate cancer cells. Furthermore, HGF also increased the production of MMP-1 and -9, MT1-MMP, u-PA and uPAR of these cells. These results suggested that HGF increased the invasive potential of prostate cancer cells probably through enhancement of cell motility and the production of MMPs and u-PA.
authors.affiliation: Department of Urology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan. fujiuchi@ms.toyama-mpu.ac.jp
authors.forename: Yasuyoshi
authors.initials: Y
authors.lastname: Fujiuchi
authors.forename: Osamu
authors.initials: O
authors.lastname: Nagakawa
authors.forename: Koji
authors.initials: K
authors.lastname: Murakami
authors.forename: Hideki
authors.initials: H
authors.lastname: Fuse
authors.forename: Ikuo
authors.initials: I
authors.lastname: Saiki
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D003094:Collagen; D004338:Drug Combinations; D005337:Fibrin / Q000378:metabolism; D017228:Hepatocyte Growth Factor / Q000494:pharmacology*; D006801:Humans; D007797:Laminin; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000235:genetics / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D009361:Neoplasm Invasiveness; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000473:pathology*; D011509:Proteoglycans; D000090063:Proto-Oncogene Mas; D012333:RNA, Messenger / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics; D011956:Receptors, Cell Surface / Q000235:genetics / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator; D011994:Recombinant Proteins / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000235:genetics / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D007797:Laminin; C000715470:MAS1 protein, human; C524898:PLAUR protein, human; D011509:Proteoglycans; D000090063:Proto-Oncogene Mas; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D011994:Recombinant Proteins; D019715:Tissue Inhibitor of Metalloproteinase-1; C059485:matrigel; D017228:Hepatocyte Growth Factor; D005337:Fibrin; D003094:Collagen; D014568:Urokinase-Type Plasminogen Activator; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1